The pathobiology of rheumatoid arthritis (RA) is similar to that of periodontitis in that proinflammatory cytokines play an important pathologic role. There is evidence to suggest that inhibitors of tumor necrosis factor (TNF) and interleukin-6 (IL-6) receptor for the treatment of RA ameliorated periodontal inflammation. However, no study has evaluated the effect of tofacitinib, an oral Janus kinase inhibitor for the treatment of RA, on periodontitis. The present report cases are 51- and 43-year-old non-smoking women with RA who demonstrated localized moderate chronic periodontitis. Both cases showed improvement in the periodontal inflammatory condition after 3 months of tofacitinib therapy, although the teeth count and supragingival bacterial plaque level were relatively unchanged. Improvements were also observed in the serum levels of IL-6 in both cases as well as in the serum levels of TNF-α and anti-cyclic citrullinated peptide immunoglobulin G in one case and of rheumatoid factor and matrix metalloproteinase-3 in the other case. Patients who received tofacitinib exhibited an inconsistent clinical response, likely due to the low disease activity of RA at the start of the administration. These are the first reported cases in which tofacitinib may have a beneficial effect on periodontitis. However, more research is required to understand the relationship between periodontitis and tofacitinib therapy.

中文翻译：

---

托法替尼对类风湿性关节炎患者牙周炎临床特征的影响：2例报告

类风湿关节炎（RA）的病理生物学与牙周炎相似，促炎细胞因子起着重要的病理作用。有证据表明，用于治疗 RA 的肿瘤坏死因子 (TNF) 和白细胞介素-6 (IL-6) 受体抑制剂可改善牙周炎症。然而，没有研究评估托法替尼（一种用于治疗 RA 的口服 Janus 激酶抑制剂）对牙周炎的影响。本报告病例是 51 岁和 43 岁的非吸烟 RA 女性，她们表现出局部中度慢性牙周炎。尽管牙齿数量和龈上菌斑水平相对没有变化，但在托法替尼治疗 3 个月后，这两个病例的牙周炎症状况都有所改善。两种病例的血清 IL-6 水平以及 TNF-α 和抗环瓜氨酸肽免疫球蛋白 G 的血清水平以及类风湿因子和基质金属蛋白酶 3 的血清水平在另一例中也有所改善. 接受托法替尼的患者表现出不一致的临床反应，这可能是由于在给药开始时 RA 的疾病活动度较低。这些是托法替尼可能对牙周炎有益的第一个报告病例。然而，需要更多的研究来了解牙周炎和托法替尼治疗之间的关系。接受托法替尼的患者表现出不一致的临床反应，这可能是由于在给药开始时 RA 的疾病活动度较低。这些是托法替尼可能对牙周炎有益的第一个报告病例。然而，需要更多的研究来了解牙周炎和托法替尼治疗之间的关系。接受托法替尼的患者表现出不一致的临床反应，这可能是由于在给药开始时 RA 的疾病活动度较低。这些是托法替尼可能对牙周炎有益的第一个报告病例。然而，需要更多的研究来了解牙周炎和托法替尼治疗之间的关系。